Compare EW & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EW | BDX |
|---|---|---|
| Founded | 1958 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9B | 43.0B |
| IPO Year | 1999 | 1998 |
| Metric | EW | BDX |
|---|---|---|
| Price | $90.78 | $190.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | $96.37 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.07 | ★ 1.59 |
| Revenue | $6,067,600,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $13.39 | N/A |
| Revenue Next Year | $9.81 | $3.02 |
| P/E Ratio | ★ $84.93 | $119.36 |
| Revenue Growth | ★ 11.55 | 8.24 |
| 52 Week Low | $72.30 | $140.11 |
| 52 Week High | $96.29 | $213.08 |
| Indicator | EW | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 73.00 |
| Support Level | $81.19 | $188.28 |
| Resistance Level | $93.91 | $196.36 |
| Average True Range (ATR) | 1.84 | 4.05 |
| MACD | -0.05 | 0.29 |
| Stochastic Oscillator | 57.21 | 85.56 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.